Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G-CSF for treatment of luteinized unruptured follicle syndrome
ChiCTR2200059797Phase 4Recruiting
- Sponsor
- Nanning Second People's Hospital
- Start
- Apr 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial in luteinized unruptured follicle syndrome (LUFS) comparing Experimental group: G-CSF with Control group: placebo (2 arms). Primary endpoint: Incidence of luteinized unruptured follicle syndrome. Started Apr 2022; status: recruiting.
02
Drugs
granulocyte colony-stimulating factor
03
Conditions
luteinized unruptured follicle syndrome (LUFS)
Beyond the preview
Go deeper on ChiCTR2200059797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200059797.